ValueScreener

ValueScreener company report

Telix Pharmaceuticals Limited (TLX)

NASDAQ / Healthcare / Biotechnology

Share price

10.57 USD Market dataClose of Oct 15, 2026

Market capitalisation

3.59B USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Feb 20, 2026
Ratios computed
Oct 15, 2026
Filed years
3, FY2023 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-1.7% Computed

From the FY2025 filing

Read quality

Valuation

Price to book

8.65x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

-1.2% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, by fiscal year

FY2015 Net income: -132.0K AUDFY2016 Net income: -44.0K AUDFY2017 Net income: -6.4M AUDFY2018 Revenue: 195.1K AUDFY2018 Net income: -13.8M AUDFY2019 Revenue: 3.5M AUDFY2019 Net income: -27.9M AUDFY2020 Revenue: 5.2M AUDFY2020 Net income: -44.9M AUDFY2022 Revenue: 160.1M AUDFY2022 Net income: -104.1M AUDFY2023 Revenue: 333.0M AUDFY2023 Net income: 4.2M AUDFY2024 Revenue: 516.6M AUDFY2024 Net income: 33.7M AUDFY2025 Revenue: 803.8M AUDFY2025 Net income: -7.1M AUD
Revenue Net income10 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.
Named tests met
0 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -1.7% in FY2025, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Biotechnology industry (494 companies), -1.7% sits at the 89th percentile; the middle half of that group runs from -146.9% to -28.9%.

Is it safe

Interest coverage was 0.73x in FY2025, in the band labelled "Distress territory" (below 1.50x), on lines anchored on Damodaran's interest-coverage table.

Year by year against peers
Whether Telix Pharmaceuticals Limited's return on equity stayed above the median of the Biotechnology industry, year by year. (FY2023 to FY2025, 3 fiscal years of Telix Pharmaceuticals Limited with a comparable figure)
The direction
Which way Telix Pharmaceuticals Limited's return on equity has moved, and how steadily. (FY2017 to FY2025, 8 filed years of Telix Pharmaceuticals Limited)
What could explain it
What in Telix Pharmaceuticals Limited's filed statements could explain the movements. (5 readings drawn from the statement lines Telix Pharmaceuticals Limited filed)
What to check next
What to check next on Telix Pharmaceuticals Limited, and where in its filings. (5 questions for Telix Pharmaceuticals Limited)
In one paragraph
One paragraph on Telix Pharmaceuticals Limited's returns, cash, balance sheet and price. (11 of sixteen figures read for Telix Pharmaceuticals Limited)

These are TLX’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research TLXPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 20-F, filed Feb 20, 2026, accession 0001628280-26-009943.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Telix Pharmaceuticals Limited: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.

n/a ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Return on equity-1.7% ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Return on capital employed, pre-tax3.2% ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Return on assets-0.6% ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Gross margin53.0% ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Operating margin3.7% ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Net margin-0.9% ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
TLX -0.9%
ARQT -4.3%TVTX -5.2%MIRM -4.5%LQDA -43.5%ZLAB -38.1%
-43.5%-0.9%
Net margin: TLX against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Telix Pharmaceuticals Limited: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity1.12 ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Current ratio1.43 ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Quick ratio1.27 ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Interest coverage0.73x ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Altman Z-score3.57 ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Net debt325.2M ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Total assets 1.16BTotal liabilities 748.6MShareholders' equity 415.4MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What Telix Pharmaceuticals Limited owned and owed at the end of fiscal 2025, from the balance sheet it filed (20-F, filed Feb 20, 2026, 0001628280-26-009943).

Telix Pharmaceuticals Limited: balance sheet position
Total assets1.16B FiledFY2025 20-F, filed Feb 20, 2026
Total liabilities748.6M FiledFY2025 20-F, filed Feb 20, 2026
Shareholders' equity415.4M FiledFY2025 20-F, filed Feb 20, 2026
Cash141.9M FiledFY2025 20-F, filed Feb 20, 2026
Total debt467.1M FiledFY2025 20-F, filed Feb 20, 2026
Net debt325.2M
Current ratio1.43
Debt to equity1.12

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

Telix Pharmaceuticals Limited: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
P/E on trailing twelve months
Why n/a

A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book8.65x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Price to sales4.47x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Enterprise value to EBIT131.54x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Enterprise value to EBITDA76.38x ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Diluted earnings per share
Why n/a

The FY2025 filing carries no diluted earnings per share we could read.

n/a FiledFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943

We publish no fair value or price target of our own. Value TLX on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Telix Pharmaceuticals Limited today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Telix Pharmaceuticals Limited: valuation
Share price10.57 USD
Market capitalisation3.59B USD
Enterprise value to EBITDA76.38x
Graham numbern/m
Diluted earnings per share, FY2022n/a

Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

Companies like Telix Pharmaceuticals Limited

  1. Arcutis Biotherapeutics, Inc. (ARQT)Market cap 3.66B USD
  2. Travere Therapeutics, Inc. (TVTX)Market cap 4.98B USD
  3. Mirum Pharmaceuticals, Inc. (MIRM)Market cap 5.35B USD
  4. Liquidia Corporation (LQDA)Market cap 3.11B USD
  5. Zai Lab Limited (ZLAB)Market cap 2.64B USD

Same industry (Biotechnology) and size band (Mid, 2B to 10B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

Telix Pharmaceuticals Limited: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield-1.2% ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Free cash flow-43.0M USD ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Free cash flow margin-5.3% ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
FY2015 Net income: -132.0K AUDFY2016 Net income: -44.0K AUDFY2017 Free cash flow: -6.0M AUDFY2017 Net income: -6.4M AUDFY2018 Free cash flow: -20.7M AUDFY2018 Net income: -13.8M AUDFY2019 Free cash flow: -23.7M AUDFY2019 Net income: -27.9M AUDFY2020 Free cash flow: 1.7M AUDFY2020 Net income: -44.9M AUDFY2022 Free cash flow: -71.0M AUDFY2022 Net income: -104.1M AUDFY2023 Free cash flow: 8.0M AUDFY2023 Net income: 4.2M AUDFY2024 Free cash flow: 18.4M AUDFY2024 Net income: 33.7M AUDFY2025 Free cash flow: -43.0M AUDFY2025 Net income: -7.1M AUD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Telix Pharmaceuticals Limited: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
8.65xFY2025Oct 15, 2026
131.54xFY2025Oct 15, 2026
-1.2%FY2025Oct 15, 2026
n/aFY2025Feb 20, 2026
n/a The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
1.12FY2025Feb 20, 2026
1.43FY2025Feb 20, 2026
4.47xFY2025Oct 15, 2026
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
3.57FY2025Oct 15, 2026
-1.56FY2025Feb 20, 2026
2/9FY2025Feb 20, 2026

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 3 filed fiscal years on record, FY2023 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 fiscal years, FY2015 to FY2025. 3 read from the annual reports Telix Pharmaceuticals Limited filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in the currency each report was stated in.

Telix Pharmaceuticals Limited: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2025803.8M USD29.8M USD-7.1M USDn/a-43.0M USD3.7%-1.7%20-F, Feb 20, 20260001628280-26-009943
FY2024516.6M USD55.2M USD33.7M USDn/a18.4M USD10.7%9.5%20-F, Feb 24, 20250001140361-25-005562
FY2023333.0M USD11.0M USD4.2M USDn/a8.0M USD3.3%4.1%20-F, Feb 24, 20250001140361-25-005562
FY2022160.1M AUD-91.9M AUD-104.1M AUD-0.34 AUD-71.0M AUD-57.4%-130.1%Market data, supplied Oct 15, 2026accession n/a
FY20205.2M AUD-44.2M AUD-44.9M AUD-0.17 AUD1.7M AUD-847.7%-56.8%Market data, supplied Oct 15, 2026accession n/a
FY20193.5M AUD-36.0M AUD-27.9M AUD-0.12 AUD-23.7M AUD-1033.6%-39.8%Market data, supplied Oct 15, 2026accession n/a
FY2018195.1K AUD-29.3M AUD-13.8M AUD-0.07 AUD-20.7M AUD-15016.1%-26.1%Market data, supplied Oct 15, 2026accession n/a
FY2017n/a-6.5M AUD-6.4M AUD-0.05 AUD-6.0M AUDn/a-12.9%Market data, supplied Oct 15, 2026accession n/a
FY2016n/a-30.0K AUD-44.0K AUD-0.00 AUDn/an/an/aMarket data, supplied Oct 15, 2026accession n/a
FY2015n/a-116.0K AUD-132.0K AUD-0.00 AUDn/an/an/aMarket data, supplied Oct 15, 2026accession n/a
  • Revenue, compound annual growth FY2018 to FY2025: 228.4%
  • Earnings: Earnings was not positive in both 2015 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2015 and 2022, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2017 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Telix Pharmaceuticals Limited: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score-1.56 ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Piotroski F-score2/9 ComputedFY2025 20-F, filed Feb 20, 2026, 0001628280-26-009943
Named tests met0 of 30 Computed
Beta
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 25 not met, 5 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
None of the named tests.
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Dividends and buybacks; Low beta, profitable; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Book or below, low debt (Walter Schloss); Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/B (David Dreman)
Not measured
ROIC at or above WACC; P/E times P/B (Benjamin Graham); Cash-covered dividend; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(14)
  • Positive Earnings Streak: The latest filed year has no per-share earnings we can read; the test needs 10.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Return on Invested Capital: The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Share Count Change Yoy: We do not hold this figure for this company, so there is nothing to show.
  • Beta: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.
  • Price Tangible Book: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by the founder: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 14 figures could not be read on this company, among them Positive Earnings Streak, P/E Ratio, Return on Invested Capital. Each blank in the table above names the rest, with its reason. 5 named tests come back incomplete because of them, which is neither met nor missed.
  • We hold 3 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy